ALK rearrangement-negative
1 drugsPredictive biomarker for patient selection in 14 indications
1
Approved Drugs
14
Indications
1
Companies
ALK rearrangement-negative is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 14 indications including Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma. Explore the targeted therapies, indications, testing methods, and companies developing ALK rearrangement-negative drugs below.
Search ALK rearrangement-negative Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting ALK rearrangement-negative
| Drug | Company | Therapeutic Area |
|---|---|---|
| OPDIVO | Bristol-Myers Squibb | Oncology |
ALK rearrangement-negative Indications
Melanoma Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma Renal Cell Carcinoma Classical Hodgkin Lymphoma Squamous Cell Carcinoma of the Head and Neck Urothelial Carcinoma Colorectal Cancer Hepatocellular Carcinoma Esophageal Cancer Gastroesophageal Junction Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Esophageal Adenocarcinoma